ALS-L1023: Clinical Trials

3 trials of ALS-L1023, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 31Terminated 1

Follow ALS-L1023: new trials by email Literature Review of ALS-L1023 trials Research Report on ALS-L1023

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH
Placebo oral tablet, ALS-L1023 1,200mg, ALS-L1023 1,800mg - Nonalcoholic Steatohepatitis
Phase 2CompletedAngioLab, Inc.602019-12-042022-08-11
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
ALS-L1023, Ranibizumab, Placebo - Age-Related Macular Degeneration
Phase 2CompletedAngioLab, Inc.1262018-12-072022-08-11
Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome
ALS-L1023, placebo - Abdominal Obesity Metabolic Syndrome
Phase 3TerminatedHanmi Pharmaceutical Company Limited2002013-05-012016-10-11

Conditions studied

Abdominal obesity metabolic syndrome (1)  ·  Macular Degeneration (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

AngioLab, Inc. (2)  ·  Hanmi Pharmaceutical Company Limited (1)

Countries

South Korea (3)

Top investigators

Dae Won Jun, Ph. D. (1)  ·  Hye Soon Park, M.D., Ph.D., M.P.H. (1)  ·  SeWoong Kang (1)